Paal (Paul) Fure Torkehagen is the Vice President of International Business Development at Medigen Vaccine Biologics Corp. (MVC). 

Since joining MVC in 2016, Paul has played a pivotal role in the company’s remarkable journey from a startup to a stock listed commercial enterprise with three approved vaccines and a solid pipeline. 

Paul leads the international sections of the innovation, strategy, and business development departments, directly reporting to the CEO.  

His daily responsibilities span across R&D, regulatory affairs, clinical trials, commercial strategy and development. He was responsible for the inclusion of MVC in the WHO ‘Solidarity Trial Vaccines’ and initiated and concluded the out-licensing of MVC’s COVID-19 vaccine through the WHO C-TAP initiative. 

Prior to his tenure at MVC, Paul worked as a senior consultant specializing in innovation and strategy, collaborating on projects with Fortune 500 companies. Simultaneously, he held the position of visiting faculty at Hult International Business School, mentoring undergraduate and graduate students in their capstone strategy and innovation projects.  

Paul has an MBA from Hult International Business School, and a BSc in Information Systems Management (ISM) with a second major in marketing from Singapore Management University.